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Pardiopulmonary Exercise Testing in the Clinical
nd Prognostic Assessment of Diastolic Heart Failure
arco Guazzi, MD, PHD, FACC,* Jonathan Myers, PHD,† Ross Arena, PHD‡
ilan, Italy; Palo Alto, California; and Richmond, Virginia
OBJECTIVES This study sought to define the relative prognostic value of cardiopulmonary exercise testing
(CPET) variables in heart failure (HF) patients with preserved versus reduced systolic
function.
BACKGROUND Cardiopulmonary exercise testing has an established role in the assessment of patients with
systolic heart failure (SHF). Two variables, peak VO2 and, more recently, the VE/VCO2 slope,
have been shown to be extremely valuable in risk stratification. However, data are lacking in
terms of the prognostic value of CPET in patients with diastolic heart failure (DHF).
METHODS A total of 409 HF patients underwent CPET. Patients were divided into three groups
according to the following left ventricular ejection fraction (LVEF) cutoffs: 40%, 45%,
and 50%. The CPET response and the ability of peak VO2 and the VE/VCO2 slope to
predict total mortality and hospitalization were examined.
RESULTS At univariate Cox regression analysis, both the peak VO2 and the VE/VCO2 slope were
significant predictors in SHF and DHF. Multivariate analysis documented a similar
prognostic power of VE/VCO2 slope and peak VO2 in all SHF groups. Conversely, in DHF
patients, VE/VCO2 slope outnumbered peak VO2, remaining the only predictor regardless of
LVEF. In DHF, the area under the receiver operating characteristic curve for the
VE/VCO2slope identified a cutoff of 32.6 (74% sensitivity, 52% specificity), 33.1 (76%
sensitivity, 62% specificity), and 33.3 (97% sensitivity, 40% specificity) for an LVEF cutoff of
40%, 45%, and 50%, respectively.
CONCLUSIONS These results extend the clinical and prognostic applicability of CPET to DHF. An
impairment in exercise ventilation rather than peak VO2 holds clinical and prognostic impact
in this increasing subset of patients. (J Am Coll Cardiol 2005;46:1883–90) © 2005 by the
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.07.051American College of Cardiology Foundation
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becent epidemiological studies have provided growing rec-
gnition that heart failure (HF) with preserved left ventric-
lar ejection fraction (LVEF) recognized as diastolic heart
ailure (DHF) is a common and costly clinical entity that is
ncreasing in prevalence (1,2). However, because of the
aucity of clinical trials addressing DHF patients, scientific
vidence regarding the natural history and clinical features
f this syndrome remains limited.
Impaired physical performance is an important hallmark
f the early stages of HF (3), and it has recently been
uggested that abnormalities in exercise metabolism are part
f the clinical scenario that limits exercise tolerance in DHF
atients (4). Cardiopulmonary exercise testing (CPET) is
he gold-standard technique for the evaluation of putative
echanisms that underlie exercise intolerance in HF (5),
nd CPET-derived indexes of cardiovascular and respira-
ory limitation have repeatedly emerged as precise predictors
f survival rate (6–12). However, studies assessing the
linical significance and prognostic power of CPET-derived
ariables have, to this point, exclusively involved patients
ith depressed LVEF or systolic heart failure (SHF). How
nd whether CPET may add to the backlog of information
From the *Cardiopulmonary Laboratory, University of Milan, San Paolo Hospital,
ilan, Italy; †VA Palo Alto Health Care System and Stanford University, Palo Alto,
alifornia; and ‡Virginia Commonwealth University, Richmond, Virginia. Presented
n part at the 77th American Heart Association Scientific Sessions, New Orleans,
ouisiana, November 7 to 10, 2004.a
Manuscript received May 7, 2005; revised manuscript received July 4, 2005,
ccepted July 18, 2005.egarding DHF patients with preserved LVEF remains
nknown.
We therefore designed the current study with two objec-
ives: 1) to explore the prognostic value of CPET variables
n the subset of DHF patients, and 2) to better examine the
hysiological response to exercise in symptomatic patients
ith DHF.
ETHODS
his was a multicenter study consisting of HF patients from
he Cardiopulmonary Laboratories at San Paolo Hospital,
ilan, Italy; the Virginia Commonwealth University, Rich-
ond, Virginia; and the VA Palo Alto Health Care System
nd Stanford University, Palo Alto, California. A total of
09 patients with chronic HF were studied during a
rogressively increasing maximal CPET. Patients who
et the Framingham criteria for congestive HF were
onsidered eligible candidates (13). Subjects with significant
bstructive lung disease evidenced as a forced expiratory
olume in 1 s 70% or who were unable to perform a
aximal exercise test were excluded from the study. Be-
ween 15% and 20% of the whole population were smokers
nd were similarly distributed across different subgroups. All
atients were in New York Heart Association functional
lass II to III.
As detailed subsequently, diastolic function was assessed
y echocardiography and Doppler-derived mitral inflow
nalysis.
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Exercise Testing in Diastolic Heart Failure November 15, 2005:1883–90Despite the fact that documentation of a normal systolic
unction (i.e., preserved LVEF) is part of the definition of
HF, considerable differences in the selection criteria for
VEF cutoffs have been reported across various studies. In
series of reports comparing patients with preserved versus
epressed systolic function, the cutoff used was a LVEF
40% (14,15). The Working Group of the European
ociety of Cardiology Guidelines (16) defined systolic
unction as being normal when LVEF is45%. Subsequent
tudies aimed at better standardizing the diagnostic criteria
f DHF have proposed a cutoff of50% (17–19). It follows
hat depending on which LVEF cutoff is used, the diagnos-
ic yield of DHF varies greatly. Accordingly, we performed
hree separate survival analyses based on the three LVEF
utoffs proposed40%,45%, and50%. The LVEF was
etermined during the initial in-hospital evaluation.
The cause of HF was coronary artery disease in 224 patients,
ypertension in 95 patients, and idiopathic cardiomyopathy
cardiac enlargement and absence of a specific reason for that)
n the rest of the patients. Other than total mortality, we
ncluded hospitalization for cardiac reasons as an end point and
erformed the analysis considering a follow-up period of one
ear. Irrespective of etiology, individuals with HF can shift
rom a stable to an uncompensated status (or vice versa) rather
bruptly. Limiting the follow-up period to one year may be
linically optimal given the fluid nature of cardiac function in
he HF patient. We recently completed an analysis of the
mpact of time past CPET on the prognostic characteristics of
he VE/VCO2 slope and peak VO2 in subjects with HF (20).
his analysis indicated that the sensitivity for predicting
utcomes increased modestly, whereas specificity dramatically
ecreased for both CPET variables after more than one year
fter exercise testing. A one-year tracking period may therefore
epresent an appropriate balance between avoiding outdated
nformation and the economic constraints of multiple exercise
ests.
Subjects were followed up for cardiac-related mortality
nd hospitalization via medical chart review at the respective
enters. Cardiac-related mortality was defined as death
irectly resulting from failure of the cardiac system. An
xample fitting this definition is myocardial infarction
ollowed by cardiac arrest. Cardiac-related hospitalization
as defined as a hospital admission directly resulting from
Abbreviations and Acronyms
CPET  cardiopulmonary exercise test
DHF  diastolic heart failure
HF  heart failure
LVEF  left ventricular ejection fraction
ROC  receiver operating characteristic
SHF  systolic heart failure
VCO2  carbon dioxide production
VE  ventilation
VO2  oxygen uptakeardiac dysfunction requiring in-patient care. An example btting this definition is decompensated HF requiring the
se of an intravenous inotropic agent. Any death or hospital
dmission with a cardiac-related discharge diagnosis, con-
rmed by diagnostic test or autopsy, was considered an
vent. Subjects in whom mortality or hospitalization was of
non-cardiac etiology were treated as censored cases.
Patients lost to follow-up were considered to be anyone
ho was not tracked for one year and did not have an event;
6 patients were not tracked for one year and were not
ncluded in the final analysis.
chocardiography. Standard M-mode and two-dimensional
chocardiography and Doppler blood flow measurements
ere performed in agreement with the American Society of
chocardiography guidelines (21). Septal and posterior LV
all thicknesses were obtained from the parasternal long-
xis view. The LV end-systolic and end-diastolic volumes
ere obtained from two-dimensional apical images. The
VEF was calculated from two-dimensional apical images
ccording to the Simpson method. The LV mass was
alculated according to the formula proposed by Devereux
t al. (22). Pulsed-wave Doppler echocardiography was used
o assess mitral peak early (E) and late (A) wave flow
elocity and E-wave deceleration time. Isovolumic relax-
tion time was also determined.
Doppler mitral in-flow velocities were used to classify
iastolic function according to the following classification:
ormal, rates of mitral E to A ratio 1 and E-wave
eceleration time 220 ms; mild, rates of mitral E to A
atio 1 and E-wave deceleration time 220 m; moderate,
ates of mitral E to A ratio 1 to 2 and E-wave deceleration
ime 150 to 200 ms; severe, rates of mitral E to A ratio 2
nd E-wave deceleration time 150 ms (1,23,24).
PET procedure and data collection. Symptom-limited
PET was performed in all patients after written informed
onsent had been obtained. All centers used individualized
amp protocols, and maximal tests were planned to obtain
n exercise duration between 8 and 10 min. Centers in the
.S. used treadmills and the Italian center used a cycle
rgometer. A potential prognostic bias derived by compar-
ng different exercise modes can reasonably be excluded
onsidering that in a previous study the comparison between
hese two modes of exercise led to the identical predictive
utoff value for both peak VO2 and VE/VCO2 slope (25).
tandard 12-lead electrocardiograms were obtained at rest,
ach minute during exercise, and for at least five minutes
uring the recovery phase; blood pressure was measured
sing a standard cuff sphygmomanometer. Minute ventila-
ion (VE, body temperature, ambient pressure, saturated with
ater), oxygen uptake (VO2, standard pressure and tempera-
ure, dry [STPD]), carbon dioxide output (VCO2, STPD) and
ther cardiopulmonary variables were acquired breath-by-
reath, averaged over 30 s, and printed in rolling averages every
0 s. The V-slope method was used to measure the anaerobic
hreshold (26). Although different methods for calculating the
E/VCO2 slope have been proposed, we measured this variable
y including all data points from the beginning to the end of
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November 15, 2005:1883–90 Exercise Testing in Diastolic Heart Failurexercise, in agreement with what has recently been shown by
ur group (27) and others (28). We reasoned that this was the
referable method for preventing variability among
aboratories.
tatistical analysis. Univariate Cox regression analysis was
sed to determine the prognostic ability of peak VO2 and
E/VCO2 slope. Multivariate Cox regression analysis was
hen performed using a forward stepwise approach to assess
he combined prognostic effects of these variables in pre-
icting total mortality and hospitalization in all HF popu-
ations. Entry and removal p values for the multivariate
nalyses were set at 0.05 and 0.10, respectively.
Receiver operating characteristic (ROC) curves were
onstructed for the peak VO2 and VE/VCO2 slope classifica-
ion schemes for the mortality end points. A z test was used
o compare peak VO2and the VE/VCO2 slope prognostic
ower (29). Optimal threshold values (highest combination
f sensitivity/specificity) were identified via ROC curve
nalysis. The threshold value was determined when the z
est showed a significant difference in area under the ROC
urve between peak VO2 and VE/VCO2 slope. Cox regression
nalysis retained only that parameter. Two threshold values
ere determined when the z test showed that the area under
he ROC curves between peak VO2 and the VE/VCO2 slope
ere not significantly different and multivariate Cox regres-
ion analysis retained both parameters. Kaplan-Meier anal-
ses and hazard ratio calculations were subsequently per-
ormed with the threshold values. The log-rank test was
sed to compare the equality of survival distributions in the
aplan-Meier analyses.
Intergroup differences between clinical and exercise vari-
bles were compared using unpaired t test analysis. All data
re reported as mean values standard deviation. Statistical
able 1. Patient Demographic and Clinical Characteristics Accor
LVEF >40%
SHF DHF
264 145
ge, yrs 56.5  13.1 58.1 
ender (men/women), % 80/20 85/1
tiology (CAD, hypertensive, idiopathic) 146/50/68 78/62
VEF, % 26.0  7.9 46.1 
PET data
Exercise time, s 540  80 555 
Peak VO2, ml·min
1·kg1 15.5  5.2 17.9 
VE/VCO2 slope 35.5  8.8 30.5 
RER 1.06  0.15 1.06 
Peak heart rate, beats/min 131.0  29.6 133.9 
herapy distribution
ACE inhibitors, % 75 70
Beta-blockers, % 45 35†
Diuretics, % 62 41†
Digoxin, % 57 35†
Aspirin, % 40 30†
Statins, % 60 50†
p  0.01 vs. SHF; †p  0.05 vs. SHF.
ACE  angiotensin-converting enzyme; CAD  coronary artery disease; CPET
jection fraction; RER  respiratory exchange ratio; SHF  systolic heart failure; Vests with a p value 0.05 were considered to be significant. mll tests were performed using SPSS for Windows version
1.0 (SPSS Inc., Chicago, Illinois).
ESULTS
ver the one-year tracking period, there were 23 deaths and 90
ospitalizations for cardiac reasons. Table 1 reports the clinical
haracteristics and CPET data of the study populations ac-
ording to LVEF cutoffs. In all groups, SHF and DHF
atients had similar age and gender distributions. A signifi-
antly lower distribution of diuretics, aspirin, statins, and
igoxin occurred in DHF patients with a LVEF 45% and
50%.
Patients exercised above their anaerobic threshold and
chieved a high peak respiratory exchange ratio (RER) (1.05
n all groups), suggesting that they developed significant
etabolic acidosis and exercised close to maximal intensity. In
ll groups, patients with SHF had a significantly lower peak
O2 and a significantly higher VE/VCO2 slope. Peak HR,
xercise time, and RER were not significantly different be-
ween SHF and DHF across identified populations.
Table 2 summarizes the echo-derived data. In all groups,
HF patients presented with significantly smaller LV volumes
nd masses. However, the ratio LV mass/LV end-diastolic
olume was significantly lower in SHF. The DHF patients,
rrespective of LVEF, showed a significantly lower E/A ratio
nd prolonged deceleration time.
Univariate Cox regression analysis showed that both peak
O2, except for the LVEF 45% group, and the VE/VCO2
lope were significant predictors of combined mortality and
ardiac-related hospitalization in SHF and DHF groups (Ta-
le 3). Multivariate Cox regression analysis (Table 4) showed
hat both peak VO2 and VE/VCO2 slope were predictors of
to Three Different LVEF Cutoffs
LVEF >45% LVEF >50%
SHF DHF SHF DHF
316 93 363 46
56.8  13.1 57.8  13.2 57.0  13.1 57.9  13.0
82/18 81/19 82/18 83/17
178/60/78 46/44/3 200/75/88 24/20/2
28.4  9.0 49.1  5.1* 30.6  10.2 53.0  4.9*
545  70 542  64 560  60 538  80
15.8  5.3 18.1  6.3* 16.1  5.5 18.4  6.8*
34.7  8.7 30.4  6.6* 34.2  8.5 30.2  7.6†
1.06  0.15 1.05  0.16 1.06  0.16 1.05  0.14
130.4  28.7 138.3  25.0 131.5  28.7 135.6  26.1
73 68† 63 63
43 34† 43 30†
60 36* 58 28*
55 30* 52 24*
45 25* 50 20*
66 44* 72 38*
diopulmonary exercise test; DHF  diastolic heart failure; LVEF  left ventricular
oxygen uptake; VE/VCO2  ventilation to carbon dioxide output.ding
13.0
5
/5
5.9*
60
6.1*
6.7*
0.17
24.3ortality in SHF groups.
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Exercise Testing in Diastolic Heart Failure November 15, 2005:1883–90In contrast, in DHF patients VE/VCO2 slope outnum-
ered peak VO2, remaining the only CPET predictor
egardless of LVEF (residual chi-square  9.9, p  0.002
or LVEF 40%; residual chi-square  8.6, p  0.003 for
VEF 45%; and residual chi-square  14.5, p  0.001
or LVEF 50%). The ROC curve analysis results for the
eak VO2 and VE/VCO2 slope classifications are presented in
able 5. In all groups of SHF and DHF patients, the area
nder the ROC curve was greater for the VE/VCO2 slope
han for peak VO2. In DHF, the best VE/VCO2 cutoff
dentified was 32.6 (sensitivity of 74% and specificity of
2%) for LVEF 40%; 33.1 (sensitivity of 76% and
pecificity of 62%) for LVEF45%; and 33.3 (sensitivity of
7% and specificity of 40%) for LVEF 50%.
Kaplan-Meier curves for the combined end point mor-
ality and cardiac-related hospitalization using these VE/
CO2 slope cutoffs for both SHF and DHF are shown in
igures 1 through 3.
able 2. Echocardiographic Data According to the Three LVEF
LVEF >40%
SHF DHF
VESV, ml 105  58 95  60*
VEDV, ml 179  60 145  65*
VM, g 255  50 230  70*
VM/LVEDV, g/ml 1.44  0.8 1.60  0.8*
itral inflow pattern
IVRT, ms 102  26 110  25
E, mm/s 90  25 65  25†
A, mm/s 36  28 85  25†
E/A ratio 2.5  0.30 0.76  0.30†
DT, ms 140  60 345  70†
p  0.01 vs. SHF; †p  0.05 vs. SHF.
A  peak mitral late velocity; DT  deceleration time; E  peak mitral early velo
VESV  left ventricular end-systolic volume; LVM  left ventricular mass; other
able 3. Univariate Cox Regression Analyses for Peak VO2 and V
Eve
VEF 40%
SHF
Peak VO2 (/14.0 ml·min
1·kg1 threshold) Mortality/ho
VE/VCO2 slope (/35.9 threshold) Mortality/ho
DHF
Peak VO2 (/14.2 ml·min
1·kg1 threshold) Mortality/ho
VE/VCO2 slope (/32.6 threshold) Mortality/ho
VEF 45%
SHF
Peak VO2 (/14.1 ml·min
1·kg1 threshold) Mortality/ho
VE/VCO2 slope (/35.6 threshold) Mortality/ho
DHF
Peak VO2 (/14.2 ml·min
1·kg1 threshold) Mortality/ho
VE/VCO2 slope (/33.1 threshold) Mortality/ho
VEF 50%
SHF
Peak VO2 (/14.3 ml·min
1·kg1 threshold) Mortality/ho
VE/VCO2 slope (/34.4 threshold) Mortality/ho
DHF
Peak VO2 (/10.6 ml·min
1·kg1 threshold) Mortality/ho
VE/VCO2 slope (/33.3 threshold) Mortality/hobbreviations as in Table 1.ISCUSSION
t is widely accepted that peak VO2, and, more recently
E/VCO2 slope, are strong prognostic markers in HF popula-
ions with impaired LV function (6–12). Previous reports
ave, however, primarily focused on the prognostic applica-
ions of CEPT variables in SHF patients. Although the
resent results confirm that in SHF patients both peak VO2
nd VE/VCO2 slope retain a prognostic value, the new finding
as that a steep VE/VCO2 slope, compared with peak VO2, is a
ore powerful prognostic marker in patients with DHF. Thus,
bnormalities in exercise ventilation that can be determined
ubmaximally and reflect the constellation of central and
eripheral factors that underlie exercise intolerance in HF
owerfully predict outcomes in both SHF and DHF. Al-
hough a need for definitive standardization of HF with
reserved systolic function or DHF has been repeatedly em-
hasized and considerable effort has been posed on it (17–19),
ffs
LVEF >45% LVEF >50%
HF DHF SHF DHF
 64 89  58† 70  62 50  57†
 65 115  65† 150  70 85  64†
 73 216  70† 220  75 200  50†
 0.7 1.90  0.9* 1.47  0.9 2.35  1.0†
 30 104  34 105  25 95  36*
 25 68  28† 80  24 75  24†
 25 80  26† 44  32 77  32†
 0.36 0.85  0.28† 1.8  0.4 0.97  0.5†
 75 320  80† 180  70 300  90†
RT  isovolumic relaxation time; LVEDV  left ventricular end-diastolic volume;
viations as in Table 1.
CO2 Slope
Number of Events Chi-Square p Value
ization 20/62 39.7 0.001
ization 20/62 48.3 0.001
ization 3/28 4.3 0.04
ization 3/28 9.9 0.002
ization 21/71 42.2 0.001
ization 21/71 50.8 0.001
ization 2/19 2.4 0.12
ization 2/19 8.6 0.003
ization 22/81 43.8 0.001
ization 22/81 48.4 0.001
ization 1/9 10.4 0.001
ization 1/9 14.5 0.001Cuto
S
98
160
240
1.50
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42
2.0
170E/V
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November 15, 2005:1883–90 Exercise Testing in Diastolic Heart Failureprecise and accepted definition is still under scrutiny. In
revious observational studies, a preserved systolic function was
efined on divergent LVEF cutoffs ranging from 40% to 50%
14–19). This obviously precludes a direct comparison between
ndings in different studies and may explain why most ques-
ions and clinical issues related to DHF remain to be answered.
o circumvent this problem, we performed the analysis by
rouping patients according to the three different LVEF
utoffs. Interestingly, in all groups categorized as DHF, VE/
CO2 slope showed a similar prognostic power regardless of the
able 4. Multivariate Cox Regression Analyses for Peak VO2 and
Predictor Variable Events
Number
Events
VEF 40%
Strongest predictor variable
VE/VCO2 slope Mortality/hospitalization 20/62
Added predicted value
from second variable
Peak VO2 Mortality/hospitalization 20/62
VEF 45%
Strongest predictor variable
VE/VCO2 slope Mortality/hospitalization 21/71
Added predicted value
from second variable
Peak VO2 Mortality/hospitalization 21/71
VEF 50%
Strongest predictor variable
VE/VCO2 slope Mortality/hospitalization 22/81
Added predicted value
from second variable
Peak VO2 Mortality/hospitalization 22/81
bbreviations as in Table 1.
Table 5. Receiving Operating Characteristics C
Mortality and Hospitalization
Area Under
the Curve
95% Confid
Interval
LVEF  40%
SHF
Peak VO2 0.76 0.70–0.82
VE/VCO2 slope 0.81 0.76–0.86
DHF
Peak VO2 0.66 0.55–0.76
VE/VCO2 slope 0.69 0.59–0.79
LVEF  45%
SHF
Peak VO2 0.76 0.70–0.81
VE/VCO2 slope 0.79 0.74–0.81
DHF
Peak VO2 0.63 0.48–0.77
VE/VCO2 slope 0.72 0.60–0.84
LVEF  50%
SHF
Peak VO2 0.74 0.72–0.82
VE/VCO2 slope 0.77 0.69–0.80
DHF
Peak VO2 0.61 0.62–0.98
VE/VCO2 slope 0.80 0.39–0.83Abbreviations as in Table 1.VEF cutoff considered. A potential additional strength of the
resent investigation stands on the use of a combined
ortality/cardiac-related hospitalization end point.
Most studies examining the prognostic value of CPET
ave not used hospitalization as an end point. Given that
F is the primary hospital diagnosis-related group among
edicare patients, and considering that the one-year read-
ission rate of DHF is nearly identical to that for SHF and
pproaches 50% (30–32), analysis of measures predicting
ospitalization in this population seems warranted.
VCO2 Slope
SHF DHF
Chi-Square p Value
Number of
Events Chi-Square p Value
48.3 0.001 3/28 9.9 0.002
17.4 0.001 3/28 1.1 0.29
50.8 0.001 2/19 8.6 0.003
16.9 0.001 2/19 1.1 0.29
48.4 0.001 1/9 14.5 0.001
20.5 0.001 1/9 1.4 0.24
Analyses for Combined End Point
p Value
Optimal Prognostic
Threshold Value
0.001 14.0 (69% sensitivity/73% specificity)
0.001 35.9 (73% sensitivity/71% specificity)
0.001 14.2 (74% sensitivity/52% specificity)
0.008 32.6 (74% sensitivity/52% specificity)
0.001 14.1 (70% sensitivity/71% specificity)
0.001 35.6 (70% sensitivity/71% specificity)
0.08 14.2 (75% sensitivity/43% specificity)
0.002 33.1 (76% sensitivity/62% specificity)
0.001 34.4 (70% sensitivity/70% specificity)
0.001 34.4 (70% sensitivity/70% specificity)
0.03 10.6 (97% sensitivity/70% specificity)
0.005 33.3 (97% sensitivity/40% specificity)VE/
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Exercise Testing in Diastolic Heart Failure November 15, 2005:1883–90E/VCO2 slope versus peak VO2: prognostic value. In a
tudy by Ponikowski et al. (33), it was observed that a
ubgroup of patients with depressed LV function but
ormal peak VO2 (18 ml · min
1 · kg1) and a VE/VCO2
igure 1. Kaplan-Meier survival curves according to VE/VCO2 slope in SH
VEF  left ventricular ejection fraction; SHF  systolic heart failure; Vigure 2. Kaplan-Meier survival curves according to VE/VCO2 slope in SH
igure 1.lope 34 had a significantly higher mortality rate than
atients with a normal peak VO2 and a VE/VCO2 slope34.
his provocative study was the first to introduce the concept
hat ventilatory inefficiency during exercise predicts mortal-
DHF using a LVEF cutoff value of40%. DHF diastolic heart failure;
ventilation; VO2  oxygen uptake.F and DHF using a LVEF cutoff value of 45%. Abbreviations as in
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November 15, 2005:1883–90 Exercise Testing in Diastolic Heart Failurety in HF even in the presence of a normal peak VO2. Our
esults confirm this observation and extend it to HF patients
ith preserved LVEF. This further challenges the belief
hat the greater the severity of the syndrome, the steeper the
E/VCO2slope; an assumption that again has been gener-
ted by the analysis of prospective trials exclusively including
atients with significant reduction in LVEF.
Interestingly, in all DHF groups the identified cutoffs for
E/VCO2 slope were definitively similar to the cutoff of 34
hat has been identified as a reference value in previous
tudies (6–12) for populations with depressed LV systolic
unction. Together, these observations suggest that an
mpairment in ventilatory efficiency should be considered a
allmark for the estimation of risk among patients with HF,
nd that these risk estimates are equally powerful among
atients with reduced and preserved systolic function. As a
arallel finding, we observed in all DHF patients that peak
O2 was significantly higher whereas VE/VCO2 slope was
ignificantly lower in DHF compared with SHF, suggesting
hat there is a significant difference in functional capacity
nd physical performance between the two conditions.
hese findings, along with the lower mortality rate, suggest
hat despite the fact that DHF is a syndrome that is
ncreasing in prevalence and that has a high morbidity, the
atural history and clinical course are less severe than those
or SHF (2,17).
PET features of DHF. In a recent study characterizing
xercise pathophysiological features of DHF, Kitzman et al.
igure 3. Kaplan-Meier survival curves according to VE/VCO2 slope in
igure 1.4) reported that, among 50 patients with DHF, the peak bxercise VE/VCO2 ratio was similar to that observed in
atients with SHF. Although average peak VO2 was lower
han that observed in our population, it was still significantly
igher in comparison with that for patients with SHF.
ifferences between the results of Kitzman et al. (4) and our
ndings may be explained by considering that the VE/VCO2
atio does not necessarily parallel the slope of this relation-
hip; identical ratios may occur with markedly different
lopes. Another important difference is that the average age
f patients was considerably higher than that in our popu-
ation, which likely accounts for the differences in peak VO2.
tudy limitations. We did not investigate the pathophysio-
ogical mechanisms that lead to ventilatory inefficiency in
atients with DHF. Specifically, we do not know the extent to
hich the increased VE/VCO2 slope is secondary to uneven
erfusion/ventilation matching, or whether it reflects muscle
econditioning with early metabolic acidosis or ergoreflex
ctivation. This is an unanswered question that needs to be
ddressed in future studies, and has important implications for
ptimizing therapeutic strategies in diastolic HF. In addition,
he total number of DHF patients was small. However, given
he recognized lower mortality rate in these patients and
onsidering our final combined end point, i.e., total mortality
nd hospitalization, the sample size seems adequate for draw-
ng preliminary conclusions. At least in patients with SHF,
eta-blocker distribution was suboptimal. The main reason is
hat, apart from patients who did not tolerate beta-blocker
itration, some patients were already receiving digoxin, and
F and DHF using a LVEF cutoff value of 50%. Abbreviations as ineta-blocker titration to high effective doses was not tolerated.
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Exercise Testing in Diastolic Heart Failure November 15, 2005:1883–90ompared with other DHF populations, the female gender
istribution in our study patients was quite low (12%)
4,34,35). This suggests that some caution may be warranted in
he extrapolation of our findings to a predominantly female
ender population of HF patients with preserved systolic
unction (4).
ONCLUSIONS
hese results extend the clinical and prognostic applicability
f CPET-derived variables to patients with DHF and
reserved LVEF. An impaired ventilation rather than peak
O2 holds clinical and prognostic impact in this population.
iven the increasing burden of DHF, our findings may help
o better characterize the natural history, treatment, and
stimation of risk in DHF.
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